---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-24-000049"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:31:55.259763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q1 net product revenue $48.1M (+40% YoY); expects Q2 cash flow positive

## Summary
- Total net revenue $50.3M (+46% YoY); net loss narrowed to $10.7M ($0.07/sh) from $26.2M.
- Restructuring completed with $50-55M annual cost savings; headcount reduced ~25%.
- Company expects to be cash flow positive (ex buybacks) in Q2 2024, ahead of prior guidance.
- Reaffirms FY2024 net product revenue guidance of $200-220M.
- FDA approved label update for LUPKYNIS removing one-year efficacy limitation; quarterly kidney assessment after year one.

## SEC filing metadata
- accession: 0001600620-24-000049
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/0001600620-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/auph-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-24-000049
- JSON: https://secwatch.observer/filing/0001600620-24-000049.json
- Plain text: https://secwatch.observer/filing/0001600620-24-000049.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported the quarter ended March 31, 2024 results: revenue $50.3 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $50.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS • Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062024000049/0001600620-24-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.